CliffBio
small molecule

ESCITALOPRAM

ESCITALOPRAM OXALATE

Loss of exclusivity—loss of exclusivity
CompanyAlmatica Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameESCITALOPRAM
Active ingredientESCITALOPRAM OXALATE
StrengthEQ 15MG BASE
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2025
Marketing statusRX

More from Almatica Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.